FDA fast tracks Novartis’ Zolgensma SMA gene replacement therapy

This article was originally published here

Zolgensma was previously granted breakthrough therapy designation by the US regulator. Novartis expects a regulatory action to be taken on the gene replacement therapy in May 2019. According

The post FDA fast tracks Novartis’ Zolgensma SMA gene replacement therapy appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply